Terns Pharmaceuticals Net Worth
Terns Pharmaceuticals Net Worth Breakdown | TERN |
Terns Pharmaceuticals Net Worth Analysis
Terns Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Terns Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Terns Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Terns Pharmaceuticals' net worth analysis. One common approach is to calculate Terns Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Terns Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Terns Pharmaceuticals' net worth. This approach calculates the present value of Terns Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Terns Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Terns Pharmaceuticals' net worth. This involves comparing Terns Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Terns Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Terns Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Terns Pharmaceuticals' net worth research are outlined below:
| Terns Pharmaceuticals generated a negative expected return over the last 90 days | |
| Terns Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (88.85 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| Terns Pharmaceuticals currently holds about 139.81 M in cash with (70.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Terns Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: William Blair Reaffirms Market Perform Rating for Terns Pharmaceuticals |
Terns Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Terns Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Terns Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Terns Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Terns Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Terns Pharmaceuticals backward and forwards among themselves. Terns Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Terns Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Superstring Capital Management Lp | 2024-12-31 | 2 M | Driehaus Capital Management Llc | 2024-12-31 | 1.7 M | Millennium Management Llc | 2024-12-31 | 1.6 M | Geode Capital Management, Llc | 2024-12-31 | 1.5 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.5 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.3 M | State Street Corp | 2024-12-31 | 1.3 M | Point72 Asset Management, L.p. | 2024-12-31 | 1.3 M | Vr Adviser, Llc | 2024-12-31 | 1.1 M | Soleus Capital Management, L.p. | 2024-12-31 | 8.1 M | Orbimed Advisors, Llc | 2024-12-31 | 7.6 M |
Follow Terns Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 284.55 M.Market Cap |
|
Project Terns Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.26) | |
| Return On Capital Employed | (0.29) | (0.31) | |
| Return On Assets | (0.24) | (0.26) | |
| Return On Equity | (0.26) | (0.27) |
When accessing Terns Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Terns Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Terns Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Terns Pharmaceuticals' management efficiency
Terns Pharmaceuticals has return on total asset (ROA) of (0.2013) % which means that it has lost $0.2013 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2956) %, meaning that it created substantial loss on money invested by shareholders. Terns Pharmaceuticals' management efficiency ratios could be used to measure how well Terns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Tangible Assets is likely to drop to -0.26. In addition to that, Return On Capital Employed is likely to drop to -0.31. As of the 22nd of March 2025, Net Tangible Assets is likely to grow to about 334.4 M, while Total Assets are likely to drop about 203.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.35 | 3.18 | |
| Tangible Book Value Per Share | 4.35 | 3.18 | |
| Enterprise Value Over EBITDA | (2.75) | (2.89) | |
| Price Book Value Ratio | 1.27 | 1.21 | |
| Enterprise Value Multiple | (2.75) | (2.89) | |
| Price Fair Value | 1.27 | 1.21 | |
| Enterprise Value | 322.4 M | 338 M |
The strategic initiatives led by Terns Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Terns Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Terns Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Terns Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Terns Pharmaceuticals Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 25th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 3rd of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Terns Pharmaceuticals Earnings per Share Projection vs Actual
Terns Pharmaceuticals Corporate Management
| David Strauss | VP Controller | Profile | |
| Pamela Danagher | Senior Assurance | Profile | |
| Debra Sieminski | Senior Affairs | Profile | |
| Jeffrey Jasper | Senior Research | Profile | |
| JD Esq | Chief Officer | Profile | |
| Senthil Sundaram | CEO Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.